Heartening results: The CUPID gene therapy trial for heart failure

Molecular Therapy

Volumn 19, Issue 7, 2011, Pages 1181-1182

  Giacca, Mauro ^a   Baker, Andrew H ^b  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; PARVOVIRUS VECTOR; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 2A; UNCLASSIFIED DRUG;

DRUG EFFICACY; EDITORIAL; ENZYME ACTIVITY; GENE OVEREXPRESSION; HEART FAILURE; HUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); VIRAL GENE DELIVERY SYSTEM;

EID: 79959990760     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.123     Document Type: Editorial

References (2)

1. Jessup, M, Greenberg, B, Mancini, D, Cappola, T, Pauly, DF, Jaski, B et al. (2011). CUPID-A Phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+ ATPase (SERCA2a) in patients with advanced heart failure. Circulation. In press.
2. Lloyd-Jones, D, Adams, RJ, Brown, TM, Carnethon, M, Dai, S, De Simone, G et al. (2010). Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 121: e46-e215.